NextCure, Inc. (NXTC)Healthcare | Biotechnology | Beltsville, United States | NasdaqGS
11.70 USD
+1.50
(14.705%)
⇧
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 19, 2026, 12:12 a.m. EDT
Despite negative fundamentals and no dividends, NXTC presents a moderate short-term opportunity due to strong positive price momentum and specific FDA/approval-related catalysts, though the downside risk remains significant given the biotech sector headwinds and negative EPS. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.089126 |
| AutoETS | 0.095410 |
| AutoARIMA | 0.095413 |
| AutoTheta | 0.103709 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.55 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.305 |
| Excess Kurtosis | -1.10 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 14.747 |
| Market Cap | 41,656,796 |
| Forward P/E | -1.85 |
| Beta | 1.58 |
| Website | https://www.nextcure.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.4314215 |
| Address1 | 9,000 Virginia Manor Road |
| Address2 | Suite 200 |
| All Time High | 1,308.0 |
| All Time Low | 2.688 |
| Ask | 15.1 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 81,790 |
| Average Daily Volume3 Month | 43,237 |
| Average Volume | 43,237 |
| Average Volume10Days | 81,790 |
| Beta | 1.58 |
| Bid | 9.36 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 9.968 |
| City | Beltsville |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.7 |
| Current Ratio | 4.14 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 13.295 |
| Day Low | 10.51 |
| Debt To Equity | 14.747 |
| Display Name | NextCure |
| Earnings Timestamp End | 1,754,308,800 |
| Earnings Timestamp Start | 1,753,873,140 |
| Ebitda | -55,431,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.09 |
| Enterprise Value | 4,991,797 |
| Eps Current Year | -8.20667 |
| Eps Forward | -6.31 |
| Eps Trailing Twelve Months | -19.65 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.9179 |
| Fifty Day Average Change | -0.21790028 |
| Fifty Day Average Change Percent | -0.018283445 |
| Fifty Two Week Change Percent | 143.14215 |
| Fifty Two Week High | 15.74 |
| Fifty Two Week High Change | -4.04 |
| Fifty Two Week High Change Percent | -0.2566709 |
| Fifty Two Week Low | 4.092 |
| Fifty Two Week Low Change | 7.608 |
| Fifty Two Week Low Change Percent | 1.8592374 |
| Fifty Two Week Range | 4.092 - 15.74 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,557,408,600,000 |
| Float Shares | 2,232,448 |
| Forward Eps | -6.31 |
| Forward P E | -1.8541996 |
| Free Cashflow | -28,799,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 40 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15177 |
| Held Percent Institutions | 0.49038 |
| Implied Shares Outstanding | 3,560,410 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,752,451,200 |
| Last Split Factor | 1:12 |
| Long Business Summary | NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. |
| Long Name | NextCure, Inc. |
| Market | us_market |
| Market Cap | 41,656,796 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_321460821 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -55,844,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 41,656,797 |
| Number Of Analyst Opinions | 3 |
| Open | 10.51 |
| Operating Cashflow | -49,613,000 |
| Operating Margins | 0.0 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 240 399 4900 |
| Previous Close | 10.2001 |
| Price Eps Current Year | -1.4256697 |
| Price Hint | 2 |
| Price To Book | 1.173756 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.967 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 1.4999 |
| Regular Market Change Percent | 14.7048 |
| Regular Market Day High | 13.295 |
| Regular Market Day Low | 10.51 |
| Regular Market Day Range | 10.51 - 13.295 |
| Regular Market Open | 10.51 |
| Regular Market Previous Close | 10.2001 |
| Regular Market Price | 11.7 |
| Regular Market Time | 1,776,715,200 |
| Regular Market Volume | 161,124 |
| Return On Assets | -0.54959 |
| Return On Equity | -1.11226 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 3,560,410 |
| Shares Percent Shares Out | 0.0156 |
| Shares Short | 55,520 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 56,033 |
| Short Name | NextCure, Inc. |
| Short Percent Of Float | 0.015800001 |
| Short Ratio | 1.44 |
| Source Interval | 15 |
| State | MD |
| Symbol | NXTC |
| Target High Price | 20.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 17.66667 |
| Target Median Price | 18.0 |
| Total Cash | 41,818,000 |
| Total Cash Per Share | 11.745 |
| Total Debt | 5,153,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -19.65 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.405345 |
| Two Hundred Day Average Change | 2.2946548 |
| Two Hundred Day Average Change Percent | 0.2439735 |
| Type Disp | Equity |
| Volume | 161,124 |
| Website | https://www.nextcure.com |
| Zip | 20,705 |